Global Factor VIII Deficiency Treatment Market 2017-2021 - Product Image

Global Factor VIII Deficiency Treatment Market 2017-2021

  • ID: 4144023
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Alnylam Pharmaceuticals
  • Biogen Idec
  • Chiesi Pharmaceutical
  • Emergent BioSolutions
  • Kedrion
  • OPKO Biologics
  • MORE
About Factor VIII

Factor VIII is an essential blood-clotting protein, which is also known as an antihemophilic factor. In individuals, factor VIII is encoded by F8 gene. Defects in F8 gene lead to hemophilia A, a recessive X-linked coagulation disorder. Factor VIII is generated in liver sinusoidal cells and endothelial cells outside the liver across the body. This protein mixes in the bloodstream in an inactive form, and binds to another molecule called von Willebrand factor, until a damage to blood vessels occur. In response to injury, coagulation factor VIII gets activated and separates from von Willebrand factor.

The analysts forecast the global factor VIII market to grow at a CAGR of 5.59% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global factor VIII market for 2017-2021. To calculate the market size, the report considers the global demand for factor VIII.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Factor VIII Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Bayer HealthCare
- CSL
- Grifols
- Novo Nordisk
- Pfizer
- Shire

Other prominent vendors
- Alnylam Pharmaceuticals
- Amarna Therapeutics
- Asklepios BioPharmaceutical
- Biogen Idec
- BioMarin Pharmaceutical
- Catalyst Biosciences
- Chiesi Pharmaceutical
- Dimension Therapeutics
- Emergent BioSolutions
- F. Hoffmann-La Roche
- Kedrion
- Octapharma
- rEVO Biologics
- OPKO Biologics
- Sangamo Therapeutics
- Spark Therapeutics
- Swedish Orphan Biovitrum
- uniQure

Market drivers
- Paradigm shift towards the development of drugs with extended half-life
- For a full, detailed list, view the full report

Market challenges
- Low diagnosis rate affecting the market growth
- For a full, detailed list, view the full report

Market trends
- Increasing investments of vendors to improve the production expertise
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the Key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Alnylam Pharmaceuticals
  • Biogen Idec
  • Chiesi Pharmaceutical
  • Emergent BioSolutions
  • Kedrion
  • OPKO Biologics
  • MORE
PART 01: Executive summary

PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
  • Highlights
PART 05: Deficiency overview

PART 06: Pipeline analysis

PART 07: Market landscape
  • Market overview
  • Five forces analysis
PART 08: Market segmentation by type of disease application
  • Global hemophilia A drugs market
  • Global hemophilia A inhibitors treatment market
  • Global von Willebrand disease treatment market
PART 09: Market segmentation by type of therapy
  • Recombinant therapies
  • Plasma-derived therapies
PART 10: Market segmentation by type of disease management
  • Prophylaxis
  • On-demand therapy
  • Inhibitor therapy
PART 11: Geographical segmentation
  • Factor VIII deficiency treatment market in Americas
  • Factor VIII deficiency treatment market in EMEA
  • Factor VIII deficiency treatment market in APAC
PART 12: Market drivers
  • Increasing adoption of prophylactic drugs
  • Paradigm shift toward the development of drugs with extended half-life
  • Large patient pool driving the shipments of factor VIII units
PART 13: Impact of drivers

PART 14: Market challenges
  • Low diagnosis rate affecting the market growth
  • High entry barriers
  • Cost-intensive complex treatment
PART 15: Impact of drivers and challenges

PART 16: Market trends
  • Increase in technological innovations
  • Development of gene therapy products
  • Expansion initiatives of vendors fueling the market growth
  • Increasing investments of vendors to improve the production capability
PART 17: Vendor landscape
  • Competitive scenario
PART 18: Key vendor analysis
  • Bayer HealthCare
  • CSL
  • Grifols
  • Novo Nordisk
  • Pfizer
  • Shire
  • Other prominent vendors
PART 19: Appendix
  • List of abbreviation
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Process of gene therapy
Exhibit 03: Key buying criteria for global factor VIII deficiency treatment market 2016 and 2021
Exhibit 04: Key customer segments of factor VIII deficiency treatment market
Exhibit 05: Pipeline analysis as of 2016
Exhibit 06: Key clinical trials
Exhibit 07: Global factor VIII deficiency treatment market snapshot
Exhibit 08: Global factor VIII deficiency treatment market 2016-2021 ($ billions)
Exhibit 09: Global factor VIII deficiency treatment market by volume 2016-2021 (million units)
Exhibit 10: Impact of factors affecting the market 2016 and 2021
Exhibit 11: Opportunity analysis in global factor VIII deficiency treatment market
Exhibit 12: Five forces analysis
Exhibit 13: Global factor VIII therapy in hemophilia A market 2016-2021 ($ millions)
Exhibit 14: Global factor VIII therapy in hemophilia A inhibitors market 2016-2021 ($ millions)
Exhibit 15: Global factor VIII therapy in von Willebrand disease treatment market 2016-2021 ($ millions)
Exhibit 16: Recombinant therapies in global factor VIII deficiency treatment market 2016-2021 ($ billions)
Exhibit 17: Plasma-derived therapies in global factor VIII deficiency treatment market 2016-2021 ($ billions)
Exhibit 18: Segmentation of factor VIII drugs market by type of disease management based on revenue 2016
Exhibit 19: Segmentation of global factor VIII deficiency treatment market based on geography 2016 and 2021
Exhibit 20: Factor VIII deficiency treatment market revenue by geography 2016-2021 (%)
Exhibit 21: Market scenario in Americas
Exhibit 22: Factor VIII deficiency treatment market in Americas 2016-2021 ($ billions)
Exhibit 23: Market scenario in EMEA
Exhibit 24: Factor VIII deficiency treatment market in EMEA 2016-2021 ($ billions)
Exhibit 25: Market scenario in APAC
Exhibit 26: Factor VIII deficiency treatment market in APAC 2016-2021 ($ billions)
Exhibit 27: Incidence rates of factor VIII deficiency
Exhibit 28: YoY shipments of factor VIII units 2012-2016 (million units)
Exhibit 29: Impact of drivers
Exhibit 30: Diagnosis and treatment trends of hemophilia A 2013
Exhibit 31: Percentage share of diagnosed and undiagnosed hemophilia population 2012-2016
Exhibit 32: Forcefield analysis of drivers and challenges
Exhibit 33: Impact of drivers and challenges
Exhibit 34: Competitive structure analysis of global factor VIII deficiency treatment market 2016
Exhibit 35: Competitive analysis of global factor VIII deficiency treatment market
Exhibit 36: Market share analysis 2016
Exhibit 37: Market penetration of various factor VIII manufacturers worldwide 2016
Exhibit 38: Strategic success factors of companies in global factor VIII deficiency treatment market
Exhibit 39: Key highlights
Exhibit 40: Bayer HealthCare: Strength assessment
Exhibit 41: Bayer HealthCare: Strategy assessment
Exhibit 42: Bayer HealthCare: Opportunity assessment
Exhibit 43: Bayer HealthCare: YoY revenue and growth rate of Kogenate 2013-2015 ($ billions)
Exhibit 44: Key highlights
Exhibit 45: CSL: Strength assessment
Exhibit 46: CSL: Strategy assessment
Exhibit 47: CSL: Opportunity assessment
Exhibit 48: Key highlights
Exhibit 49: Grifols: Strength assessment
Exhibit 50: Grifols: Strategy assessment
Exhibit 51: Grifols: Opportunity assessment
Exhibit 52: YoY growth rate and revenue of bioscience segment 2013-2015 ($ billions)
Exhibit 53: Key highlights
Exhibit 54: Novo Nordisk: Strength assessment
Exhibit 55: Novo Nordisk: Strategy assessment
Exhibit 56: Novo Nordisk: Opportunity assessment
Exhibit 57: Novo Nordisk: YoY revenue and growth of hemophilia segment 2013-2015
Exhibit 58: Key highlights
Exhibit 59: Pfizer: Strength assessment
Exhibit 60: Pfizer: Strategy assessment
Exhibit 61: Pfizer: Opportunity assessment
Exhibit 62: Pfizer: YoY revenue and growth rate of Xyntha/ReFacto AF 2013-2015 ($ millions)
Exhibit 63: Key highlights
Exhibit 64: Shire: Strength assessment
Exhibit 65: Shire: Strategy assessment
Exhibit 66: Shire: Opportunity assessment
Exhibit 67: Baxalta: YoY revenue comparison of hemophilia segment 2013-2015 ($ billions)
Exhibit 68: Baxalta: Geographic segmentation of hemophilia by revenue 2015
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Alnylam Pharmaceuticals
  • Biogen Idec
  • Chiesi Pharmaceutical
  • Emergent BioSolutions
  • Kedrion
  • OPKO Biologics
  • MORE
New Report Released: – Global Factor VIII Market 2017-2021

The author of the report recognizes the following companies as the key players in the global factor VIII market: Bayer HealthCare, CSL, Grifols, Novo Nordisk, Pfizer, and Shire

Other Prominent Vendors in the market are: Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios BioPharmaceutical, Biogen Idec, BioMarin Pharmaceutical, Catalyst Biosciences, Chiesi Pharmaceutical, Dimension Therapeutics, Emergent BioSolutions, F. Hoffmann-La Roche, Kedrion, Octapharma, rEVO Biologics, OPKO Biologics, Sangamo Therapeutics, Spark Therapeutics, Swedish Orphan Biovitrum, and uniQure

Commenting on the report, an analyst from the research team said: “Currently, most of the hemophilia therapeutics available in the market are short-acting, i.e., used only when the individual is bleeding. Apart from this, it is also observed that many of these products exhibit immunogenic reactions, which result in a reduced therapeutic effect of these products. In order to mitigate these issues, technologies such as recombinant DNA, protein fusion technology, and PEGylation technologies were developed and applied in the production of new therapies with a longer lifespan and fewer immunogenic reactions. For instance, Biogen is developing rFVIIIFc, a recombinant next-generation therapeutic product for hemophilia A therapy. It is the firm’s leading product and is a truncated version of factor VIII, fused to the Fc domain of an antibody, which extends the half-life of the product in the bloodstream. This recombinant product is developed using Biogen's protein fusion technology. Thus, an increase in technological innovations is expected to drive the global hemophilia drugs market during the forecast period.”

According to the report, the prophylactic treatment approach helps in preventing spontaneous bleeding episodes, increases the quality of life in terms of physical activities, and retains the level of clotting factors above a baseline. Further, the use of prophylactic drugs could reduce the economic burden on factor VIII treatment. It also helps in reducing joint damage and suffering from pain. Most short-acting therapeutics exhibit immunogenic reactions, which led to people adopting long-acting therapeutics. Therefore, the vendors are focusing on the development of prophylactic drugs. For instance, in September 2015, F. Hoffmann La-Roche received breakthrough therapy designation for ACE910, a prophylactic treatment for individuals of ages 12 and above. In March 2015, Novo Nordisk launched Novoeight in the US for the routine prophylaxis to prevent the frequency of bleeding episodes, control and prevention of bleeding, and perioperative management. In June 2014, Biogen Idec received the US FDA approval of Eloctate for the control and prevention of bleeding, perioperative management and routine prophylaxis in individuals with hemophilia A. Such initiatives are expected to drive the market growth.

Further, the report states that the diagnosis rates of hemophilia A is very low, especially in the developing countries like China and India. In the developed regions such as Germany, Australia, and the US, the disease diagnosis rate is more than 80%. However, in developing countries such as China, India, and Indonesia, disease diagnosis rates are 56%, 12%, and 4%, respectively. The low diagnosis rate of hemophilia in developing countries is due to inadequate treatment facilities, limited disease knowledge, and a shortage of treatment supplies. Along with such limitations, the lack of proper diagnosis can cause complications at later stages, negatively affecting individual's quality of life.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Bayer HealthCare
  • CSL
  • Grifols
  • Novo Nordisk
  • Pfizer
  • Shire
  • Alnylam Pharmaceuticals
  • Amarna Therapeutics
  • Asklepios BioPharmaceutical
  • Biogen Idec
  • BioMarin Pharmaceutical
  • Catalyst Biosciences
  • Chiesi Pharmaceutical
  • Dimension Therapeutics
  • Emergent BioSolutions
  • F Hoffmann-La Roche
  • Kedrion
  • Octapharma
  • rEVO Biologics
  • OPKO Biologics
  • Sangamo Therapeutics
  • Spark Therapeutics
  • Swedish Orphan Biovitrum
  • uniQure
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll